Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
LONDON — AstraZeneca said Tuesday it has had to resubmit a closely watched medicine for U.S. approval in a different form of ...
AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Kyodo News on MSN3h
Central Japan nuclear unit fails post-Fukushima safety checkJapan's nuclear watchdog formally decided Wednesday that a reactor in central Japan has failed to pass a safety review needed ...
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Chugoku Electric Power Company has announced that it plans to resume operation of unit 2 at its Shimane nuclear power plant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback